Treatment Information

Back

Breast Cancer treatment details. Chemotherapy.

M.D. Anderson Cancer Center, Houston, Texas, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Houston, Texas
Treatments:ChemotherapyHospital:M.D. Anderson Cancer Center
Drugs:Journal:Link
Date:Sep 2005

Description:

Patients: This Phase II study involved 63 women with advanced metastatic breast cancer. The mean age was 48.2 years. Forty-five women were from Indian-Eastern descent, while fourteen were Caucasian. Metastatic sites included lung, liver, and bone. Only sixteen patients did not receive chemotherapy prior to treatment.

Treatment: The treatment consisted of one agent: ABI-007, which is a nanoparticle containing a biologically interactive albumin-bound form of paclitaxel.

Toxicity: One patient died as a result of possibly treatment-related
cardiac ischemia/infarction. Grade 3-4 toxicities included neutropenia, leukopenia, anemia, fatigue, sensory neuropathy, myalgia, and diarrhea.

Results: The median overall survival was 14.7 months (63.6 weeks). Two patients had a complete response, and 28 had a partial response to treatment. The authors concluded that the ABI-007 form of paclitaxel "allows for safe administration of high paclitaxel doses without premedication, resulting in significant antitumor activity in patients with MBC, including those receiving the drug as first-line therapy."

Correspondence: Nuhad K. Ibrahim, MD



Back